bullish
WuXi Biologics IPO Review - An Opportunity to Get Exposure to Biologics in China
783 Views01 Jun 2017 09:29
WuXi Biologics (2269 HK) is looking to raise US$461-511m through the issuance of primary (88%) and secondary (12%) shares. Proceeds will be used...
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 11-minute read)
Discussions
(Paid Plans Only)
Zhen Zhou, Toh
APAC IPOs & Placements
Price Chart(Sign Up to Access)
- Wuxi Biologics Placement - Probably Not a Surprise to Sell Again when Lock-Up Expires19 Jun 2018
- Wuxi Biologics Placement - In Time for the Next Lock-Up, Returns Will Probably Not Match Prior Ones21 Mar 2018
- Wuxi Biologics Placement - Selldown Right when Lockup Expires Suggests Eagerness to Offload13 Dec 2017
- WuXi Biologics: Pass on This Valuation27 May 2017
- WuXi Biologics: Updated Valuation Data17 May 2017
x